Gut

Article	Citations
Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19	794
Mucus barrier, mucins and gut microbiota: the expected slimy partners?	693
Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection	670
Gut microbiome and health: mechanistic insights	669
Gut microbiota-derived metabolites as central regulators in metabolic disorders	509
Interaction between drugs and the gut microbiome	441
Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report	384
Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites	373
Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process	367
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications	363
Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN	305
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort	291
Global burden of oesophageal and gastric cancer by histology and subsite in 2018	287
Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome	274
Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health	265
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study	257
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases	248
Practice of endoscopy during COVID-19 pandemic: position statements of the Asian Pacific Society for Digestive Endoscopy (APSDE-COVID statements)	247
Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome	240
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus	230
Faecal calprotectin indicates intestinal inflammation in COVID-19	230
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals	227
Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents	226
Effect of IBD medications on COVID-19 outcomes: results from an international registry	217
COVID-19 and immunomodulation in IBD	210

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic	208
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome	206
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD	199
Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19	193
The role of gut microbiota in cancer treatment: friend or foe?	188
Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a National Endoscopy Database Analysis	187
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis	179
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) imm	175
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting	166
Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study	166
Guidelines on the management of ascites in cirrhosis	164
Calprotectin: from biomarker to biological function	162
Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology	162
Alterations in the human oral and gut microbiomes and lipidomics in COVID-19	161
COVID-19 and the gastrointestinal tract: more than meets the eye	157
Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial	157
Helicobacter pyloriresistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community	154
Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing	152
Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching	150
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores	150
Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort	150
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab	144
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups	144
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis	141
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning	138
Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications	136
European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients	135
Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis	132
Adipose tissue derived bacteria are associated with inflammation in obesity and type 2 diabetes	128
Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide	126
F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer	126
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease	123
Rapid gut dysbiosis induced by stroke exacerbates brain infarction in turn	122
Diet quality and risk and severity of COVID-19: a prospective cohort study	122
Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study	122
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges	121
Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation	120
Six-month follow-up of gut microbiota richness in patients with COVID-19	119
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies	119
Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial	115
COVID-19 in an international European liver transplant recipient cohort	113
Low risk of COVID-19 transmission in GI endoscopy	112
Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade	107
A faecal microbiota signature with high specificity for pancreatic cancer	106
Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis	106
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic	105
Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer	105
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives	104
Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis	104
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?	103

Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19	102
Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19	102
Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis	100
Artificial intelligence and colonoscopy experience: lessons from two randomised trials	100
Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study	100
Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma	99
Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort	98
Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma	98
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series	98
Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure	98
Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16	97
Recent advances in clinical practice: epidemiology of autoimmune liver diseases	95
Host and gut microbial tryptophan metabolism and type 2 diabetes: an integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies	93
Lactobacillus gallinarummodulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis	93
Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury	92
Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic func	91
Dysosmobacter welbionis is a newly isolated human commensal bacterium preventing diet-induced obesity and metabolic disorders in mice	91
Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning	90
British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults	89
Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population	89
Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women	89
Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis	89
Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism	87
Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites	86
Disrupted spermatogenesis in a metabolic syndrome model: the role of vitamin A metabolism in the gut–testis axis	86
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies	84
Angiogenin maintains gut microbe homeostasis by balancing α-Proteobacteria and Lachnospiraceae	84
Novel therapeutic targets for cholestatic and fatty liver disease	84
Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events	84
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification	83
Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment	82
Current therapies and new developments in NASH	82
Blue poo: impact of gut transit time on the gut microbiome using a novel marker	82
Targeting the gut-liver-immune axis to treat cirrhosis	81
Machine learning in GI endoscopy: practical guidance in how to interpret a novel field	81
LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover	80
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes	79
Early gastric cancer detection in high-risk patients: a multicentre randomised controlled trial on the effect of second-generation narrow band imaging	79
Accuracy of a no-biopsy approach for the diagnosis of coeliac disease across different adult cohorts	79
Piecemeal cold snare polypectomy versus conventional endoscopic mucosal resection for large sessile serrated lesions: a retrospective comparison across two successive periods	78
Involvement of liver in COVID-19: systematic review and meta-analysis	77
Long-term yield of pancreatic cancer surveillance in high-risk individuals	76
Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett’s oesophagus and provides insights into clinical heterogeneity in reflux d	75
Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis	75
Liquid biopsy in the clinical management of hepatocellular carcinoma	75
Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial	75
ABC score: a new risk score that accurately predicts mortality in acute upper and lower gastrointestinal bleeding: an international multicentre study	74
Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom	73
Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis	72
Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity	71
High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cells	71
MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis	70
Loss of hepatic Mboat7 leads to liver fibrosis	69
Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project)	69
Improvement in sperm quality and spermatogenesis following faecal microbiota transplantation from alginate oligosaccharide dosed mice	69
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future	68
Estimating the environmental impact of disposable endoscopic equipment and endoscopes	66
Utilisation of artificial intelligence for the development of an EUS-convolutional neural network model trained to enhance the diagnosis of autoimmune pancreatitis	66
Advancing human gut microbiota research by considering gut transit time	65
Gastric per-oral endoscopic myotomy (G-POEM) for refractory gastroparesis: results from an international prospective trial	65
Prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score	64
Western-type diet influences mortality from necrotising pancreatitis and demonstrates a central role for butyrate	64
Underdevelopment of the gut microbiota and bacteria species as non-invasive markers of prediction in children with autism spectrum disorder	63
Chinese Consensus Report on Family-BasedHelicobacter pyloriInfection Control and Management (2021 Edition)	63
CXCR2 inhibition enables NASH-HCC immunotherapy	63
Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers	63
Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update	63
ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1–TFAM signalling in alcoholic steatohepatitis	62
RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer	61
Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis	61
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial	61
Critical thresholds: key to unlocking the door to the prevention and specific treatments for acute pancreatitis	60
Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet	59
SARS-CoV-2 infection in acute pancreatitis increases disease severity and 30-day mortality: COVID PAN collaborative study	59
Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea	58
Mass eradication ofHelicobacter pylorito reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands	58
Human and preclinical studies of the host–gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health	57
Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulce	57
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer	57
Equivalent performance of single-use and reusable duodenoscopes in a randomised trial	57

PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF	56
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma	56
Long-term outcomes after endoscopic treatment for Barrett’s neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period	56
Location-specific cell identity rather than exposure to GI microbiota defines many innate immune signalling cascades in the gut epithelium	56
Proton pump inhibitors and risk of gastric cancer: population-based cohort study	56
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease	55
Recent advances in clinical practice: colorectal cancer chemoprevention in the average-risk population	55
Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance	55
Bidirectional brain–gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis	55
A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis	55
British Society of Gastroenterology guidelines on the management of functional dyspepsia	54
Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP)	54
Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study	54
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size	54
Severe liver failure during SARS-CoV-2 infection	54
Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis	53
Niche-specific functional heterogeneity of intestinal resident macrophages	53
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database	53
FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2	53
TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms	53
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis	53
Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study	53
Interplay between diet and gut microbiome, and circulating concentrations of trimethylamine N-oxide: findings from a longitudinal cohort of US men	52
Dietary macronutrients and the gut microbiome: a precision nutrition approach to improve cardiometabolic health	52
Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny	51
Multiomics analysis reveals the presence of a microbiome in the gut of fetal lambs	51
Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance	51
Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study	51
Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial	50
Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy	50
Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment	50
The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma	50
Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis	50
Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes	49
Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade	49
Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts	49
N6-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression	49
Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world	48
Impairment of gut microbial biotin metabolism and host biotin status in severe obesity: effect of biotin and prebiotic supplementation on improved metabolism	48
YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition	48
Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis	48
Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers	48
Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer	47
Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression	47
Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer	47
Oncogenetic landscape of lymphomagenesis in coeliac disease	47
COVID-19 and liver disease	47
Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation	47
Genomic evolution and diverse models of systemic metastases in colorectal cancer	47
Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions	46
Effectiveness of one-time endoscopic screening programme in prevention of upper gastrointestinal cancer in China: a multicentre population-based cohort study	45
Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care	45
Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma	45
Mapping the human gut mycobiome in middle-aged and elderly adults: multiomics insights and implications for host metabolic health	45
Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases	45
Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma	44
Inflammatory bowel disease and Parkinson’s disease: common pathophysiological links	44
Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial	44
From the origin of NASH to the future of metabolic fatty liver disease	43
PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicabil	43
Rapid resolution of COVID-19 after faecal microbiota transplantation	43
COVID-19 infection in Crohn’s disease under treatment with adalimumab	43
Effect of resolvins on sensitisation of TRPV1 and visceral hypersensitivity in IBS	42
Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer	42
Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies	42
Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients	42
Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPG	42
Emerging treatment options for extraintestinal manifestations in IBD	42
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study	42
Genetic architectures of proximal and distal colorectal cancer are partly distinct	41
Organoids in gastrointestinal diseases: from experimental models to clinical translation	41
Autoimmune gastritis: long-term natural history in naïveHelicobacter pylori-negative patients	40
GI symptoms as early signs of COVID-19 in hospitalised Italian patients	40
Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource	40
NAIL: an evolutionarily conserved lncRNA essential for licensing coordinated activation of p38 and NFκB in colitis	39
Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc–xCT	39
Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease	39
TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection	39
Safely restarting GI endoscopy in the era of COVID-19	39
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells	39
One world, one pandemic, many guidelines: management of liver diseases during COVID-19	38
Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases	38
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications	38
Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease	38
Global prevalence of Barrett’s oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis	38
Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System	38
Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment	38
Serotonin is elevated in COVID-19-associated diarrhoea	37
Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa	37
SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation	37
Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo	37
Non-compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer	37
6α-hydroxylated bile acids mediate TGR5 signalling to improve glucose metabolism upon dietary fiber supplementation in mice	36
Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds	36
Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection	36